Table 3.
Univariate and multivariate analysis of overall survival.
| Risk factor | The entire cohort | The PSM cohort | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age level (<60/≥60) | 0.7 (0.41–1.21) | 0.206 | 0.99 (0.51–1.95) | 0.987 | ||||
| Gender (M/F) | 0.99 (0.42–2.29) | 0.971 | 1.16 (0.41–3.26) | 0.786 | ||||
| Pathogenesis | ||||||||
| HBV | Reference | 0.127 | 2.14 (0.97–4.71) | 0.06 | Reference | 0.723 | ||
| HCV | 2.03 (0.63–6.55) | 0.236 | 1.98 (0.87–4.52) | 0.106 | 1.41 (0.33–5.98) | 0.642 | ||
| Unclear | 0.39 (0.12–1.25) | 0.114 | 0.52 (0.07–3.82) | 0.523 | ||||
| Type of PVTT (I+II/III+IV) | 1.12 (0.68–1.82) | 0.658 | 1.12 (0.6–2.12) | 0.718 | ||||
| Local lymphatic metastasis (no/yes) | 1.04 (0.55–1.95) | 0.907 | 1.1 (0.46–2.62) | 0.835 | ||||
| Recurrence (no/yes) | 0.89 (0.47–1.67) | 0.708 | 1.09 (0.5–2.39) | 0.825 | ||||
| TACE frequency (<3, ≥3) | 0.34 (0.18–0.65) | 0.001 | 0.34 (0.18–0.66) | 0.001 | 0.39 (0.17–0.9) | 0.028 | 0.35 (0.15–0.82) | 0.016 |
| Size (<7/≥7) | 1.56 (0.91–2.7) | 0.109 | 1.28 (0.66–2.49) | 0.474 | ||||
| Number of Tumor | 1.38 (0.84–2.26) | 0.202 | 1.56 (0.83–2.94) | 0.165 | ||||
| Tumor Location | ||||||||
| Right Lobe | Reference | 0.265 | Reference | 0.592 | ||||
| Left Lobe | 0.72 (0.22–2.36) | 0.592 | 0.85 (0.2–3.65) | 0.824 | ||||
| Both Lobe | 1.44 (0.87–2.4) | 0.158 | 1.36 (0.71–2.59) | 0.354 | ||||
| HBV DNA | ||||||||
| Absent | Reference | 0.043 | Reference | 0.287 | ||||
| Present | 2.39 (1.1–5.19) | 0.028 | 1.88 (0.7–5.02) | 0.208 | ||||
| Unknown | 2.76 (1.23–6.17) | 0.014 | 2.28 (0.82–6.33) | 0.114 | ||||
| ECOG (<2/≥2) | 2.31 (1.37–3.9) | 0.002 | 2.06 (1.21–3.5) | 0.008 | 1.96 (1.27–3.8) | 0.045 | 1.63 (0.8–3.33) | 0.178 |
| APT (s) | ||||||||
| ≤40 | Reference | 0.482 | Reference | 0.644 | ||||
| 40 < x ≤ 75,000 | 0.63 (0.25–1.59) | 0.329 | 0.61 (0.22–1.75) | 0.361 | ||||
| >75,000 | 0.88 (0.28–2.77) | 0.826 | 0.72 (0.19–2.69) | 0.628 | ||||
| Child-Pugh (A/B) | 2.37 (0.94–5.99) | 0.067 | 2.89 (0.68–12.27) | 0.149 | ||||
| AFP (<400/≥400 ng/ml) | 1.36 (0.82–2.27) | 0.236 | 0.98 (0.51–1.9) | 0.96 | ||||
| PIVKA-II (<900/≥900, ng/ml) | 1.58 (0.9–2.78) | 0.108 | 2.06 (0.97–4.39) | 0.061 | 2.26 (0.99–5.15) | 0.053 | ||
| Hemoglobin (<100/≥100) | 0.26 (0.09–0.74) | 0.001 | 0.39 (0.09–1.66) | 0.203 | ||||
| WBC (<4/≥412/L) | 0.67 (0.39–1.17) | 0.161 | 0.69 (0.34–1.39) | 0.297 | ||||
| PLT (<100/≥1009/L) | 1.11 (0.61–2.03) | 0.730 | 1.52 (0.67–3.46) | 0.321 | ||||
| ALT (<35/≥35 IU/L) | 1.02 (0.61–1.7) | 0.944 | 1.3 (0.68–2.48) | 0.426 | ||||
| AST (<35/≥35 IU/L) | 1.02 (0.5–2.08) | 0.953 | 0.99 (0.41–2.37) | 0.976 | ||||
| Treatment (TACE-L/TACE-S) | 0.31 (0.79–2.13) | 1.293 | 2.21 (1.12–4.38) | 0.022 | 1.93 (0.96–3.88) | 0.660 | ||
M, Male; F, Female; HBV, Hepatitis B virus; HCV, Hepatitis C virus; PVTT, Portal vein tumor thrombus; ECOG, Eastern cooperative oncology group; PIVKA-II, Protein Induced by Vitamin K absence or antagonist-II; AFP, Alpha fetoprotein; WBC, White blood cells; PLT, Platelet count; ALT, Alanine transaminase; AST, Aspartate aminotransferase.